Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its news flow reflects this specialized focus. Company announcements frequently highlight developments related to its three commercial-stage products—EXPAREL, ZILRETTA and iovera°—as well as its gene therapy candidate PCRX-201 for osteoarthritis of the knee.
On this page, readers can follow Pacira news such as commercial partnerships, clinical data, manufacturing updates and shareholder-related events. Recent releases include an agreement granting LG Chem exclusive rights to commercialize EXPAREL in select Asia-Pacific markets, preliminary revenue updates emphasizing EXPAREL sales, and data from a pilot study showing favorable safety and pain reduction with iovera° compared with radiofrequency ablation in chronic low back pain.
Pacira also issues news about its participation in scientific and investor conferences, including presentations at major healthcare conferences, and its involvement in collaborative research efforts. For example, the company announced that it joined the PROBE Consortium, a public‑private initiative using big data and AI to improve osteoarthritis research and care, and that it will contribute data from its ASCEND study of PCRX-201.
In addition, Pacira’s news includes corporate and financial updates such as preliminary unaudited revenue results, share repurchase activity, inducement equity grants under its inducement plan, and operational changes like workforce reductions linked to manufacturing efficiency improvements. External parties such as DOMA Perpetual Capital Management LLC have also issued public letters and proxy-related communications concerning Pacira’s governance and strategic options.
Investors, analysts and healthcare professionals can use this news feed to monitor product performance, pipeline progress, strategic partnerships, financing developments and shareholder actions that may influence the outlook for PCRX stock and Pacira’s role in non-opioid pain management.
Pacira BioSciences (Nasdaq: PCRX) appointed Samit Hirawat, M.D. to its Board of Directors effective Jan. 28, 2026, increasing the board to 10 members. Dr. Hirawat brings more than 25 years of clinical development experience, including senior roles at Bristol Myers Squibb and Novartis.
This appointment highlights added clinical and oncology development expertise to support Pacira’s commercial portfolio and pipeline of non-opioid pain therapies, including next-generation gene therapy efforts.
Pacira (NASDAQ: PCRX) announced an exclusive agreement with LG Chem to commercialize EXPAREL (bupivacaine liposome injectable suspension) in select Asia-Pacific markets.
Under the deal, Pacira will manufacture EXPAREL and receive an undisclosed upfront payment, a transfer price, and tiered royalties on future sales; LG Chem will pursue regulatory approvals and plans to file for marketing authorizations in South Korea and Thailand within six months. The partnership is intended to expand patient access to opioid-sparing postsurgical pain control and advance Pacira’s 5x30 strategy.
Pacira (Nasdaq: PCRX) reported preliminary, unaudited total revenue of $726.4 million for the year ended December 31, 2025, up from $701.0 million in 2024. Full-year EXPAREL net product sales were $575.1 million (volume +6%), with fourth-quarter EXPAREL sales of $155.8 million (Q4 volume +7%). Full-year ZILRETTA sales were $116.6 million and iovera° sales were $24.2 million in 2025. The company repurchased 2.0 million shares for $50.0 million in Q4 and had 41.1 million shares outstanding at December 31, 2025, with $150.0 million remaining on its repurchase authorization. On January 5, 2026, Pacira granted inducement awards totaling 36,300 shares equivalent (14,000 option shares; 22,300 RSUs) to ten new employees. Results are preliminary and unaudited.
Pacira BioSciences (Nasdaq: PCRX) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 AM PST (2:15 PM EST). Live audio will be available via the company’s Events page at investor.pacira.com. A replay of the webcast will be accessible for two weeks following the presentation.
This presentation offers investors and analysts direct access to management commentary and company updates on Pacira’s non-opioid pain therapy commercial and development priorities.
Summary not available.
Pacira Biosciences (NASDAQ: PCRX) joined the PROBE Consortium on Dec. 18, 2025 to help accelerate osteoarthritis (OA) research and care.
Pacira will contribute data from its ASCEND study of investigational gene therapy PCRX-201 and collaborate with 38 partners in an IHI-funded public-private consortium to create a regulation-compliant database, apply AI to predict disease progression, develop multi-modal trial endpoints, and build shared decision-making tools—leveraging data from over 70 million patients across OA cohorts and real-world registries.
Pacira BioSciences (Nasdaq: PCRX) announced that on December 1, 2025 it granted inducement restricted stock unit awards to two newly hired employees under its Amended and Restated 2014 Inducement Plan, approved by the People & Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
The awards total an aggregate of 2,200 restricted stock units, each representing the contingent right to one share of common stock. The RSUs vest in four equal annual installments beginning December 1, 2026, and vesting is conditioned on continued employment and the terms of each award agreement.
Pacira BioSciences (NASDAQ: PCRX) reported 12-month results from a 30-patient randomized pilot comparing iovera° cryoneurolysis to radiofrequency ablation (RFA) for facet-mediated chronic low back pain. The study found significantly lower pain scores with iovera° at Day 180 (3.1 vs 5.4, p=0.01) and Day 360 (3.0 vs 6.1, p=0.01), and better functional outcomes by Oswestry Disability Index at Day 360 (10.1 vs 20.6, p=0.002). Fewer iovera° patients required additional spine injections after 180 days (45.5% vs 75%). No treatment-related adverse events were reported during 12 months. The trial was unblinded and device length limited use to lower BMI patients; a new FDA-cleared SmartTip for deeper lumbar access was noted.
Summary not available.
Pacira BioSciences (Nasdaq: PCRX) will participate in analyst-led fireside chats at two upcoming healthcare conferences: the Jefferies London Healthcare Conference on Nov 18, 2025 at 1:30 PM GMT (8:30 AM ET) and the 37th Annual Piper Sandler Healthcare Conference on Dec 2, 2025 at 1:30 PM ET.
Live audio of both events will be available on the company’s Events page at investor.pacira.com, and webcasts will be replayable for two weeks after each event.
FAQ
What is the current stock price of Pacira Biosciences (PCRX)?
What is the market cap of Pacira Biosciences (PCRX)?
